The University of Chicago Header Logo

Connection

Michael R. Bishop to Graft vs Host Disease

Back to Details
This is a "connection" page, showing publications Michael R. Bishop has written about Graft vs Host Disease.
Michael R. Bishop
Connection Strength
3.631
Graft vs Host Disease
  1. Donor lymphocyte infusion: beauty is in the eye of the beholder. Biol Blood Marrow Transplant. 2013 Jun; 19(6):849-50.
    View in: PubMed
    Score: 0.381
  2. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008 Dec 10; 26(35):5735-41.
    View in: PubMed
    Score: 0.280
  3. Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1022-30.
    View in: PubMed
    Score: 0.256
  4. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1150-60.
    View in: PubMed
    Score: 0.244
  5. Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol. 2004 Mar; 2(3):237-45.
    View in: PubMed
    Score: 0.202
  6. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023 02 28; 7(4):549-554.
    View in: PubMed
    Score: 0.189
  7. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2002 Apr; 29(8):709-10.
    View in: PubMed
    Score: 0.177
  8. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.
    View in: PubMed
    Score: 0.153
  9. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.
    View in: PubMed
    Score: 0.152
  10. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
    View in: PubMed
    Score: 0.146
  11. Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion. Chin Med J (Engl). 2013 Nov; 126(22):4380-8.
    View in: PubMed
    Score: 0.099
  12. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 2013 Apr 11; 121(15):2864-74.
    View in: PubMed
    Score: 0.094
  13. Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Dec; 47(12):1552-7.
    View in: PubMed
    Score: 0.089
  14. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1619-29.
    View in: PubMed
    Score: 0.083
  15. Development of severe sclerotic chronic GVHD during treatment with dasatinib. Bone Marrow Transplant. 2010 Sep; 45(9):1469-70.
    View in: PubMed
    Score: 0.076
  16. Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. Emerg Med Clin North Am. 2009 May; 27(2):311-31.
    View in: PubMed
    Score: 0.072
  17. Principles and overview of allogeneic hematopoietic stem cell transplantation. Cancer Treat Res. 2009; 144:1-21.
    View in: PubMed
    Score: 0.071
  18. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol. 2007 Nov; 110(5):1041-9.
    View in: PubMed
    Score: 0.065
  19. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):22-30.
    View in: PubMed
    Score: 0.057
  20. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005 Apr; 78(4):265-74.
    View in: PubMed
    Score: 0.055
  21. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol. 2004 Sep; 126(6):837-43.
    View in: PubMed
    Score: 0.052
  22. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 2004 May; 33(10):1031-5.
    View in: PubMed
    Score: 0.051
  23. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant. 2003 Mar; 9(3):162-9.
    View in: PubMed
    Score: 0.047
  24. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000 Jul 01; 96(1):80-5.
    View in: PubMed
    Score: 0.039
  25. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr; 25(7):717-22.
    View in: PubMed
    Score: 0.039
  26. Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist. 2000; 5(6):487-96.
    View in: PubMed
    Score: 0.038
  27. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.033
  28. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.
    View in: PubMed
    Score: 0.033
  29. Potential use of hematopoietic stem cells after radiation injury. Stem Cells. 1997; 15 Suppl 2:305-10.
    View in: PubMed
    Score: 0.031
  30. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplant. 1996 Oct; 18(4):747-53.
    View in: PubMed
    Score: 0.030
  31. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.029
  32. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13.
    View in: PubMed
    Score: 0.029
  33. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Exp Hematol. 1995 Dec; 23(14):1503-8.
    View in: PubMed
    Score: 0.029
  34. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13.
    View in: PubMed
    Score: 0.024
  35. Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Exp Hematol. 2013 Sep; 41(9):772-8.
    View in: PubMed
    Score: 0.024
  36. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant. 2013 Aug; 48(8):1056-64.
    View in: PubMed
    Score: 0.024
  37. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15; 120(20):4256-62.
    View in: PubMed
    Score: 0.023
  38. Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol. Health Qual Life Outcomes. 2011 Apr 17; 9:24.
    View in: PubMed
    Score: 0.021
  39. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1037-69.
    View in: PubMed
    Score: 0.019
  40. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):871-90.
    View in: PubMed
    Score: 0.019
  41. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2007 Feb; 35(2):184-92.
    View in: PubMed
    Score: 0.015
  42. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol. 2005 Aug 20; 23(24):5788-94.
    View in: PubMed
    Score: 0.014
  43. Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells. Semin Oncol. 2004 Feb; 31(1):56-67.
    View in: PubMed
    Score: 0.013
  44. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Cytotherapy. 2003; 5(6):542-52.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.